Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30877212.
- Also identified by DOI 10.3899/jrheum.181072 and PMC identifier 7254610.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV). An international Delphi exercise conducted among investigators identified items considered important to measure active disease. In parallel, qualitative research with patients was conducted, including interviews and focus groups. Next steps prioritized by the group for LVV include (1) defining disease states (remission, flare, and patient-acceptable symptom state) and (2) selection of patient-reported outcome tools. The ultimate goal is to develop an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV.
Medical subject headings
- Giant Cell Arteritis
- Takayasu Arteritis